Foto del docente

Margherita Nannini

Research fellow

Department of Experimental, Diagnostic and Specialty Medicine - DIMES

Curriculum vitae

Date of birth: May 17, 1982

Education and training:

  • 14/07/2001: Graduation at the High School, Liceo Classico “L. Galvani”, Bologna (vote: 100/100).
  • 11/06/2007: Degree in Medicine and Surgery, University of Bologna. Thesis Title: “Study of gene expression profiling of colorectal liver metastases”. Result: 110/100 cum laude
  • 2008 March – October 2012: Specialization training program in Medical Oncology at Department of Hematology and Oncological Sciences “L.A. Seragnoli”, S.Orsola-Malpighi Hospital, University of Bologna
  • 30 October 2012: Specialization in Medical Oncology at Department of Hematology and Oncological Sciences “L.A. Seragnoli”, S.Orsola-Malpighi Hospital, University of Bologna. Thesis title: “Genomic Analysis of KIT/PDGFRA Wild-type (WT) gastrointestinal stromal tumors (GIST) with next generation sequencing approach”. Vote: 70/70 cum laude

Position

  • From August 1, 2015: Researcher at Department of Specialized, Experimental and Diagnostic Medicine of the University of Bologna, conducting the project entitled: “Biology and treatment of rare tumors on a molecular basis as a clinical model in medical oncology”.

Membership

  • Member of GISTStudyGroup and SarcomaStudyGroup of Bologna at Sant'Orsola-Malpighi Hospital.
  • Member of Italian Sarcoma Group (ISG)
  • Member of ESMO

Award

  • May 14 to 15, 2013 (Prague): award for the best case study presented at ARCHEOLOGIST Summit 2013.

Lectures

  • Palermo, April 3-4, 2012: Highlights GIST: mutations beyond -kit and PDGFRA;
  • Firenze, September 24-25, 2012: GASTRO IN 2012: Gastrointestinal Stromal Tumors (GIST):
  • Prague, 14-15 May, 2013: ARCHEOLOGIST Summit 2013 - Tailoring therapy with sunitinib in a elderly patient with advanced GIST;
  • Padova, April 7-8, 2014: XVIII ITALIAN SARCOMA GROUP ANNUAL MEETING: Novelty of 2014: KIT/PDGFRA mutational analysis on peripheral blood.
  • Bologna, April 11, 2014: PDTA GIST e sarcomi addominali: un’esperienza da esportare
  • Firenze, April 10-11, 2015: XIX ITALIAN SARCOMA GROUP ANNUAL MEETING: GIST: novelty of GIST molecular biology.
  • Cremona, May 7-8, 2015: GIST: molecular basis of targeted therapy in GIST
  • Bologna, March 17, 2016: Medical therapy and locoregional treatment in GIST: an integrated approach
  • Bologna, September 27, 2017: the importance of the reference centres for GIST

Clinical trials:
Co-investigator according to Good Clinical Practice in:

  • Pfizer A6181112: A phase IIIB, randomized, active, controlled, open-label study of SUNITINIB (SUTENT) 37.5 mg daily vs Imatinib Mesylate 800 mg daily in the treatment of patients with Gastrointestinal Stromal Tumors (GIST) who have had progressive disease while on 400 mg daily of Imatini
  • A randomized, open-label, multi-center study to evaluate the efficacy of nilotinib versus best supportive care with or without a tyrosine kinase inhibitor (investigator's choice) in adult patients with gastrointestinal stromal tumors resistant to both imatinib and sunitinib
  • A randomized, open-label, multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST)
  • A dose-finding phase Ib multicenter study of imatinib in combination with the oral phosphatidyl-inositol 3-kinase (PI3K) inhibitor ByL719 in patients with gastrointestinal stromal tumor (GIST) who failed prior therapy with imatinib and sunitinib.
  • TRAVELL "A Phase II study on Trabectedin in advanced retroperitoneal leiomyosarcoma and well differentiated/dedifferentiated liposarcoma”

Research field:
Main research fields:

  • Gastrointestinal tumors
  • Soft Tissue Sarcomas

Selected peer-reviewed publications (Selected from 58 peer-reviewed publications), most relevant to the current application:

  1. Nannini M, Nigro MC, Vincenzi B, et al. Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice. Ther Advances Med Oncol 2017;9(12): 731-739.
  2. Ravegnini G, Sammarini G, Nannini M, Pantaleo MA, Biasco G, Hrelia P, Angelini S. Gastrointestinal stromal tumors (GIST): Facing cell death between autophagy and apoptosis. Autophagy. 2017 Mar 4;13(3):452-463
  3. Nannini M, Urbini M, Astolfi A, Biasco G, Pantaleo MA. The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST). J Transl Med. 2017 May 23;15(1):113.
  4. De Simone B, Ansaloni L, Sartelli M, Coccolini F, Di Saverio S, Pantaleo MA, Saponara M, Nannini M, Abongwa HK, Napoli JA, Catena F. What is changing in the surgical treatment of gastrointestinal stromal tumors after multidisciplinary approach? A comprehensive literature's review. Minerva Chir. 2017 Feb 14
  5. Ravegnini G, Nannini M, Zenesini C, Simeon V, Sammarini G, Urbini M, Gatto L,Saponara M, Biasco G, Pantaleo MA, Venturoli N, Hrelia P, Angelini S. An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure. Angiogenesis. 2017 Feb;20(1):139-148.
  6. Pantaleo MA, Urbini M, Indio V, Ravegnini G, Nannini M, De Luca M, Tarantino G, Angelini S, Gronchi A, Vincenzi B, Grignani G, Colombo C, Fumagalli E, Gatto L, Saponara M, Ianni M, Paterini P, Santini D, Pirini MG, Ceccarelli C, AltimariA, Gruppioni E, Renne SL, Collini P, Stacchiotti S, Brandi G, Casali PG, Pinna AD, Astolfi A, Biasco G. Genome-wide Analyses Identifies MEN1 and MAX Mutation and a Neuroendocrine-like Molecular Heterogeneity in Quadruple WT GIST. Mol Cancer Res. 2017 May;15(5):553-562
  7. Gatto L, Nannini M, Saponara M, Di Scioscio V, Beltramo G, Frezza GP, Ercolani G, Pinna AD, Astolfi A, Urbini M, Brandi G, Biasco G, Pantaleo MA. Radiotherapy in the management of gist: state of the art and new potential scenarios. Clin Sarcoma Res. 2017 Jan 10;7:1.
  8. Ravegnini G, Nannini M, Simeon V, Musti M, Sammarini G, Saponara M, Gatto L, Urbini M, Astolfi A, Biasco G, Pantaleo MA, Venturoli N, Hrelia P, Angelini S. Polymorphisms in DNA repair genes in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome.Tumour Biol 2016;37(10):13413-13423
  9. Pantaleo MA, Nannini M. Long-term outcome of molecular subgroups of gastrointestinal stromal tumour patients treated with standard-dose imatinib in the BFR14 trial: The wild-type gastrointestinal stromal tumours are not a single group yet. Eur J Cancer. 2016 Feb 28;58:38-40.
  10. Saponara M, Urbini M, Astolfi A, Indio V, Ercolani G, Del Gaudio M, Santini D, Pirini MG, Fiorentino M, Nannini M, Lolli C, Mandrioli A, Gatto L, Brandi G, Biasco G, Pinna AD, Pantaleo MA. Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS). Oncotarget. 2015 Dec 8;6(39):42243-57.
  11. Astolfi A, Urbini M, Indio V, Nannini M, Genovese CG, Santini D, Saponara M, Mandrioli A, Ercolani G, Brandi G, Biasco G, Pantaleo MA. Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST). BMC Genomics. 2015 Nov 3;16:892.
  12. Nannini M, Ravegnini G, Angelini S, Astolfi A, Biasco G, Pantaleo MA. miRNA profiling in gastrointestinal stromal tumors: implication as diagnostic and prognostic markers. Epigenomics. 2015 Sep;7(6):1033-49.
  13. Vincenzi B, Nannini M, Fumagalli E, Bronte G, Frezza AM, De Lisi D, Spalato Ceruso M, Santini D, Badalamenti G, Pantaleo MA, Russo A, Dei Tos AP, Casali P, Tonini G. Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. Oncotarget. 2015 Sep 24 [Epub ahead of print].
  14. Urbini M, Astolfi A, Indio V, Heinrich MC, Corless CL, Nannini M, Ravegnini G, Biasco G, Pantaleo MA. SDHC methylation in gastrointestinal stromal tumors (GIST): a case report. BMC Med Genet. 2015 Sep 28;16:87.
  15. Minichillo S, Pantaleo MA, Nannini M, Coccolo F, Gatto L, Biasco G, Brandi G. Efficacy of weekly docetaxel in locally advanced cardiac angiosarcoma. BMC Res Notes. 2015 Jul 30;8:325.
  16. Ravegnini G, Nannini M, Sammarini G, Astolfi A, Biasco G, Pantaleo MA, Hrelia P, Angelini S. Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA Analysis. Int J Mol Sci. 2015 Jul 9;16(7):15592-608.
  17. Nannini M, Biasco G, Pantaleo MA; The GIST Study Group, Bologna. An immunohistochemical study of potential diagnostic and therapeutic biomarkers of wild type gastrointestinal stromal tumours - Letter to the editor. Histopathology. 2015 Nov;67(5):746-7
  18. Saponara M, Pantaleo MA, Nannini M, Biasco G. Treatments for gastrointestinal stromal tumors that are resistant to standard therapies. Future Oncol. 2014 Oct;10(13):2045-59.
  19. Nannini M, Astolfi A, Urbini M, Indio V, Santini D, Heinrich MC, Corless CL, Ceccarelli C, Saponara M, Mandrioli A, Lolli C, Ercolani G, Brandi G, Biasco G, Pantaleo MA. Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST). BMC Cancer 2014;14:685.
  20. Angelini S, Ravegnini G, Nannini M, Bermejo JL, Musti M, Pantaleo MA, Fumagalli E, Venturoli N, Palassini E, Consolini N, Casali PG, Biasco G, Hrelia P. Folate-related polymorphisms in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome. Eur J Hum Genet. 2015 Jun;23(6):817-23.
  21. Saponara M, Lolli C, Nannini M, DI Scioscio V, Serra C, Mandrioli A, Pallotti MC, Biasco G, Pantaleo MA. Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours. Oncol Lett 2014;8(4):1793-1799.
  22. Pantaleo MA, Lolli C, Nannini M, Astolfi A, Indio V, Saponara M, Urbini M, La Rovere S, Gill A, Goldstein D, Ceccarelli C, Santini D, Rossi G, Fiorentino M, Di Scioscio V, Fusaroli P, Mandrioli A, Gatto L, Catena F, Basso U, Ercolani G, Pinna AD, Biasco G. Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations. Genet Med. 2015 May;17(5):391-5.
  23. Pantaleo MA, Nannini M, Corless CL, Heinrich MC. Quadruple wild-type (WT) GIST: defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways. Cancer Med. 2015 Jan;4(1):101-3.
  24. Pantaleo MA, Astolfi A, Urbini M, Fuligni F, Saponara M, Nannini M, Lolli C, Indio V, Santini D, Ercolani G, Brandi G, Pinna AD, Biasco G. Dystrophin deregulation is associated with tumor progression in KIT/PDGFRA mutant gastrointestinal stromal tumors. Clin Sarcoma Res. 2014;4:9.
  25. Nannini M, Astolfi A, Urbini M, Biasco G, Pantaleo MA. Liquid biopsy in gastrointestinal stromal tumors: a novel approach. J Transl Med. 2014;12:210.
  26. Pantaleo MA, Nannini M, Astolfi A, Biasco G. Novel Clinically Relevant Genes in GIST--Letter. Clin Cancer Res. 2014 Apr 1;20(7):2014
  27. Nannini M, Biasco G, Astolfi A, Urbini M, Pantaleo MA. Insulin-like Growth Factor (IGF) system and gastrointestinal stromal tumours (GIST): present and future. Histol Histopathol. 2014 Feb;29(2):167-75
  28. Nannini M, Astolfi A, Biasco G, Pantaleo MA. An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST). J Med Genetics 2013 Oct;50(10):653-61
  29. Nannini M, Pantaleo MA, Biasco G. Role of molecular analysis in the adjuvant treatment of gastrointestinal stromal tumours: it is time to define it. World J Gastroenterol. 2013;19:2583-6.
  30. Pantaleo MA, Astolfi A, Urbini M, Nannini M, Paterini P, Indio V, Saponara M, Formica S, Ceccarelli C, Casadio R, Rossi G, Bertolini F, Santini D, Pirini MG, Fiorentino M, Basso U, Biasco G. Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFRA wild-type GIST. Eur J Hum 2014 Jan;22(1):32-9
  31. Pallotti MC, Pantaleo MA, Nannini M, Centofanti F, Fabbrizio B, Montanari M, Baraldi O, Saponara M, Lolli C, Mandrioli A, Biasco G, Prandini R. Development of a Nephrotic Syndrome in a Patient with Gastrointestinal Stromal Tumor during a Long-Time Treatment with Sunitinib. Case Rep Oncol 2012;5(3):651-6.
  32. Nannini M, Astolfi A, Paterini P, Urbini M, Santini D, Catena F, Indio V, Casadio R, Pinna AD, Biasco G, Pantaleo MA. Expression of IGF-1 receptor in KIT/PDGF receptor-α wild-type gastrointestinal stromal tumors with succinate dehydrogenase complex dysfunction. Future Oncol. 2013 Jan;9(1):121-6.
  33. Catena F, Di Battista M, Ansaloni L, Pantaleo M, Fusaroli P, Di Scioscio V, Santini D, Nannini M, Saponara M, Ponti G, Persiani R, Delrio P, Coccolini F, Di Saverio S, Biasco G, Lazzareschi D, Pinna A. Microscopic margins of resection influence primary gastrointestinal stromal tumor survival. Onkologie. 2012;35(11):645-8.
  34. Angelini S, Pantaleo MA, Ravegnini G, Zenesini C, Cavrini G, Nannini M, Fumagalli E, Palassini E, Saponara M, Di Battista M, Casali PG, Hrelia P, Cantelli-Forti G, Biasco G. Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy. Pharmacol Res. 2012 Nov 2;68(1):1-6.
  35. Nannini M, Pantaleo MA, Catena F, Romano S, Tondo S, Pirini MG, Lolli C, Maleddu A, Mandrioli A, Gatto L, Saponara M, Pallotti MC, Dei Tos AP, Pinna AD, Biasco G. Surgical second-look in high risk gastrointestinal stromal tumor of small intestine: A case report. Int J Surg Case Rep. 2012 Sep 19;4(1):7-10.
  36. Nannini M, Pantaleo MA, Maleddu A, Saponara M, Mandrioli A, Lolli C, Pallotti MC, Gatto L, Santini D, Paterini P, DI Scioscio V, Catena F, Fusaroli P, Pinna AD, Tos AP, Biasco G. Duration of adjuvant treatment following radical resection of metastases from gastrointestinal stromal tumours. Oncol Lett. 2012;3:677-681.
  37. Pantaleo MA, Mandrioli A, Saponara M, Nannini M, Erente G, Lolli C, Biasco G. Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. BMC Cancer. 2012 Jun 11;12:231.
  38. Saponara M, Pantaleo MA, Nannini M, Biasco G. Chronic therapy in gastrointestinal stromal tumours (GISTs): the big gap between theory and practice. Target Oncol. 2012 Dec;7(4):243-6
  39. Lolli C, Pantaleo MA, Nannini M, Saponara M, Pallotti MC, Scioscio VD, Barbieri E, Mandrioli A, Biasco G. Successful radiotherapy for local control of progressively increasing metastasis of gastrointestinal stromal tumor. Rare Tumors 2011;3:e49.
  40. Pantaleo MA, Astolfi A, Nannini M, Ceccarelli C, Formica S, Santini D, Heinrich MC, Corless C, Dei Tos AP, Paterini P, Catena F, Maleddu A, Saponara M,Di Battista M, Biasco G. Differential expression of neural markers in KIT and PDGFRA wild-type gastrointestinal stromal tumours. Histopathology 201159:1071-80.
  41. Pantaleo MA, Nannini M, Astolfi A, Biasco G; GIST Study Group Bologna. A distinct pediatric-type gastrointestinal stromal tumor in adults: potential role of succinate dehydrogenase subunit A mutations. Am J Surg Pathol 2011;35:1750-2

  42. Nannini M, Biasco G, Maleddu A, Pantaleo MA. New molecular targets beyond KIT and PDGFRA in gastrointestinal stromal tumors (GISTs): present and future. Expert Opin Ther Targets. 2011 Jul;15(7):803-15.

  43. Nannini M, Pantaleo MA, Biasco G. The follow-up after radical surgery of colorectal cancer: is it time for a “tailored” strategy? Clin Colorectal Cancer 2011 Jun;10(2):81-4

  44. Nannini M, Biasco G, Pallotti MC, Di Battista M, Santini D, Paterini P, Maleddu A, Mandrioli A, Lolli C, Saponara M, Di Scioscio V, Zompatori M, Catena F, Fusaroli P, Dei Tos AP, Pantaleo MA. Late recurrences of gastrointestinal stromal tumours (GISTs) after 5 years of follow-up. Med Oncol. 2012 Mar;29(1):144-50.
  45. Pantaleo MA, Nicoletti G, Nanni C, Gnocchi C, Landuzzi L, Quarta C, Boschi S, Nannini M, Di Battista M, Castellucci P, Fanti S, Lollini PL, Bellan E, Castelli M, Rubello D, Biasco G. Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. J Exp Clin Cancer Res. 2010 Dec 30;29:173

  46. Nannini M, Biasco G, Di Scioscio V, Di Battista M, Zompatori M, Catena F, Castellucci P, Paterini P, Dei Tos AP, Stella F, Maleddu A, Pantaleo MA. Clinical, radiological and biological features of lung metastases in gastrointestinal stromal tumors (case reports). Oncol Rep. 2011 Jan;25(1):113-20.

  47. Nannini M, Pantaleo MA, Paterini P, Piazzi G, Ceccarelli C, La Rovere S, Maleddu A, Biasco G. Molecular detection of epidermal growth factor receptor (EGFr) in colorectal cancer: does it still make sense? Colorectal Dis. 2011 May;13(5):542-8
  48. Pantaleo MA, Nannini M, Di Battista M, Catena F, Biasco G. Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy. Cancer Treat Rev. 2010 Feb;36(1):63-8.
  49. Di Cicilia R, Castellucci P, Nannini M, Balbi T, Zannetti G, Fanti S, Biasco G, Pantaleo MA. Unusual finding of benign Abrikossoff tumor by F-18 FDG-PET mimicking melanoma recurrence. Clin Nucl Med. 2009 Oct;34(10):696-7.
  50. Maleddu A, Pantaleo MA, Castellucci P, Astorino M, Nanni C, Nannini M, Busato F, Di Battista M, Farsad M, Lodi F, Boschi S, Fanti S, Biasco G. 11C-acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma. Tumori. 2009 May-Jun;95(3):382-4.
  51. Pantaleo MA, Astolfi A, Nannini M, Biasco G. The emerging role of insulin-like growth factor 1 receptor (IGF1r) in gastrointestinal stromal tumors (GISTs). J Transl Med. 2010 Nov 15;8:117.
  52. Pantaleo MA, Di Battista M, La Rovere S, Astorino M, Catena F, Lolli C, Saponara M, Maleddu A, Nannini M, Di Scioscio V, Santini D, Ceccarelli C, Paterini P, Castellucci P, Astolfi A, Mandrioli A, Fusaroli P, Tomassetti P, Pinna AD, Biasco G. Management of patients with gastrointestinal stromal tumor in clinical practice in Italy: a critical "event tree model" analysis of decision-making processes and outcomes. Tumori. 2010 Mar-Apr;96(2):219-28.
  53. Astolfi A, Nannini M, Pantaleo MA, Di Battista M, Heinrich MC, Santini D, Catena F, Corless CL, Maleddu A, Saponara M, Lolli C, Di Scioscio V, Formica S, Biasco G. A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number. Lab Invest. 2010 Sep;90(9):1285-94.
  54. Pantaleo MA, Nannini M, Di Battista M, Catena F, Biasco G. Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy. Cancer Treat Rev. 2010 Feb;36(1):63-8.
  55. Di Cicilia R, Castellucci P, Nannini M, Balbi T, Zannetti G, Fanti S, Biasco G, Pantaleo MA. Unusual finding of benign Abrikossoff tumor by F-18 FDG-PET mimicking melanoma recurrence. Clin Nucl Med. 2009 Oct;34(10):696-7.
  56. Maleddu A, Pantaleo MA, Castellucci P, Astorino M, Nanni C, Nannini M, Busato F, Di Battista M, Farsad M, Lodi F, Boschi S, Fanti S, Biasco G. 11C-acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma. Tumori. 2009 May-Jun;95(3):382-4.
  57. Pantaleo MA, Astolfi A, Di Battista M, Heinrich MC, Paterini P, Scotlandi K, Santini D, Catena F, Manara MC, Nannini M, Maleddu A, Saponara M, Lolli C, Formica S, Biasco G. Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target. Int J Cancer. 2009 Dec 15;125(12):2991-4.
  58. Pantaleo MA, Nannini M, Fanti S, Boschi S, Lollini PL, Biasco G. Molecular imaging of EGFR: it's time to go beyond receptor expression. J Nucl Med. 2009 Jul;50(7):1195-6; author reply 1196, 1197.

  59. Nannini M, Nobili E, Di Cicilia R, Brandi G, Maleddu A, Pantaleo MA, Biasco G. To widen the setting of cancer patients who could benefit from metronomic capecitabine. Cancer Chemother Pharmacol. 2009 Jun;64(1):189-93.

  60. Nannini M, Pantaleo MA, Maleddu A, Astolfi A, Formica S, Biasco G. Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives. Cancer Treat Rev. 2009 May;35(3):201-9.
  61. Pantaleo MA, Nannini M, Maleddu A, Fanti S, Nanni C, Boschi S, Lodi F, Nicoletti G, Landuzzi L, Lollini PL, Biasco G. Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. Ann Oncol. 2009 Feb;20(2):213-26.
  62. Pantaleo MA, Astolfi A, Nannini M, Paterini P, Piazzi G, Ercolani G, Brandi G, Martinelli G, Pession A, Pinna AD, Biasco G. Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice. Br J Cancer. 2008 Nov 18;99(10):1729-34.
  63. Brandi G, Nannini M, Pantaleo MA, Fanello S, Farsad M, Fanti S, Ercolani G, Maleddu A, Di Battista M, Biasco G. Molecular imaging suggests efficacy of bevacizumab beyond the second line in advanced colorectal cancer patients. Chemotherapy. 2008;54(6):421-4.
  64. Pantaleo MA, Nannini M, Lopci E, Castellucci P, Maleddu A, Lodi F, Nanni C, Allegri V, Astorino M, Brandi G, Di Battista M, Boschi S, Fanti S, Biasco G. Molecular imaging and targeted therapies in oncology: new concepts in treatment response assessment. a collection of cases. Int J Oncol. 2008 Sep;33(3):443-52.
  65. Pantaleo MA, Fanti S, Nannini M, Boschi S, Nanni C, Maleddu A, Rubello D, Biasco G. What oncologists need and require from nuclear medicine. Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1761-5.
  66. Pantaleo MA, Nannini M, Maleddu A, Fanti S, Ambrosini V, Nanni C, Boschi S, Biasco G. Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. Cancer Treat Rev. 2008 Apr;34(2):103-21.
  67. Pantaleo MA, Saponara M, Nannini M, Biasco G. Targeted therapies in solid tumours: results and promises. Minerva Med. 2007 Oct;98(5):603-23. Review.

Latest news

At the moment no news are available.